Pediatric Long-Term Follow-up and Rollover Study

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

Trial Details

NCT ID
NCT03975829
Phase
PHASE4
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • dabrafenib
  • trametinib
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Miami, Florida, United States|25.77427,-80.19366
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • All Subjects:
  • Written informed consent, according to local guidelines, signed by the subjects and/or by the parents or legal guardian prior to any study related …
  • Participation in a Novartis sponsored study such as CTMT212X2101, CDRB436G2201, CDRB436A2102, regardless of current age.
  • Parent study (or cohort of parent study) is planned to be closed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →